Incyte2026年收入预期疲软，加剧市场对Jakafi专利的担忧

Core Viewpoint - Incyte's annual revenue forecast is below Wall Street expectations, raising concerns about the company's ability to offset the impact of the upcoming patent expiration of its best-selling drug, Jakafi [1][2][3] Revenue Forecast - Incyte expects revenue in 2026 to be between $4.77 billion and $4.94 billion, significantly lower than the analyst average estimate of $5.52 billion [3] - The weak forecast highlights the pressure on Opzelura, which is expected to generate revenue of $750 million to $790 million in 2026, below the analyst estimate of $801.5 million [3] Drug Performance - Opzelura's sales surged by 28% to $207.3 million in the fourth quarter, exceeding the expected $195.6 million, yet the company remains cautious about future projections [3] - Jakafi, Incyte's flagship drug for treating blood cancers, is projected to have sales of $3.22 billion to $3.27 billion in 2026, higher than the analyst estimate of $3.09 billion [4] Earnings and Milestones - In the fourth quarter, Jakafi's sales grew by 7% to $828.2 million, surpassing market expectations [5] - Incyte reported adjusted earnings per share of $1.80, below the analyst estimate of $1.93, with total revenue reaching $1.51 billion, exceeding the expected $1.35 billion due to a $100 million milestone payment [5]